The results of this study show that novel chA21 scFv-based, HER2-specific CAR T cells not only recognised and killed HER2+ breast and ovarian cancer cells ex vivo but also induced regression of experimental breast cancer in vivo. Here, ERBB2 is linked to ovarian cancer.